Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)
Sponsor: Clinical Trials in Organ Transplantation
Terminated
Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.
Other terminated trials from Clinical Trials in Organ Transplantation
- Kidney Transplantation · Phase PHASE2 · Apr 2016
- Cardiac Allograft Vasculopathy · Phase PHASE2 · Oct 2015
- Kidney Transplant Recipients · Phase PHASE2 · May 2015
- Heart Transplant · Phase PHASE2 · Jul 2014
See all terminations from Clinical Trials in Organ Transplantation
Other Kidney Transplantation trials with similar outcome
A PHASE2 clinical study on Kidney Transplantation and Renal Transplantation, this trial is terminated or withdrawn. The trial is conducted by Clinical Trials in Organ Transplantation and has accumulated 8 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Trials in Organ Transplantation
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .